Home › Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...
 

Keywords :   


Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer...

2015-05-30 21:49:00| Logistics - Topix.net

Clovis Oncology today announced updated Phase 2 results from two ongoing clinical studies with rucaparib: ARIEL2 and Study 10. Rucaparib is the Company's investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of advanced ovarian cancer, specifically in patients with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as "BRCA-like." Updated data from the ARIEL2 study in 204 patients with advanced ovarian cancer are being presented Monday in an oral presentation by Professor Iain McNeish at the 2015 American Society of Clinical Oncology annual meeting in Chicago.

Tags: studies phase cancer ovarian

Category:Transportation and Logistics

Latest from this category

All news
29.09Atlantic Tropical Weather Outlook
29.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Summary for Hurricane Isaac (AT5/AL102024)
28.09Hurricane Isaac Public Advisory Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
Transportation and Logistics »
29.09When to recline and how to share armrests: Rules for avoiding a mid-flight row
29.09Atlantic Tropical Weather Outlook
29.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
More »